JAN 03, 2017 01:03 PM PST

Novel Pathway Found for Antibiotic Resistance in Immunocompromised Patients

Increased incidence of infections in hospitals caused by antibiotic-resistant bacteria has been a serious and ongoing challenge facing hospitals worldwide. Immunocompromised patients such as people receiving chemotherapy are extremely susceptible to these infections. Scientists at St. Jude Children’s Research Hospital have discovered a novel pathway used by enterococcus bacteria to tolerate standard and long-term antibiotic treatment specifically in immunocompromised patients.

The research project started with a 6-week old patient who was being treated for acute myeloid leukemia. After cancer treatment depleted her white blood cell count, she contracted a blood stream infection with vancomycin-resistant Enterococcus faecium (VRE) that was vigorously treated with antibiotics. While the antibiotics were ineffective, the infection cleared up as soon as her immune system recuperated to full function.

Co-corresponding authors Joshua Wolf, MBBS, and Jason Rosch, Ph.D., of the St. Jude Department of Infectious Diseases. (St. Jude Children's Research Hospital / Peter Barta)

Clinicians worked to understand why the infection was resistant to antibiotics but susceptible to the immune system. The group, led by Jason Rosch, Ph.D., and Joshua Wolf, MBBS, both assistant members of the St. Jude Department of Infectious Diseases, looked to in-depth DNA sequencing to understand the conundrum.

The team sequenced the DNA of 22 VRE samples collected from the infection and found a linked single missense mutation in the relA gene of VRE. The relA gene mediates the ‘stringent response’ in cells, a pathway used by bacteria to survive stressful environments and antibiotic use. The pathway also elevates levels of the signaling molecule alarmone, which appears to help the bacteria survive multiple antibiotic treatments.

"These findings detail a 'perfect storm' for development of antibiotic tolerance by bacteria that already pose a clinical challenge," said Dr. Rosch. "The same conditions may be present in other patients with immune systems that have been compromised by chemotherapy or disease," added Dr. Wolf.

The mutant bacteria were especially resistant to high doses of antibiotics when growing in biofilms. Biofilm growth is common in hospitals, where development on catheters, heart valves and other surfaces causes infection. Biofilms are protected by persister cells that grow in a dormant top layer and act as a barrier against the immune system and antibiotic therapy. Two of the antibiotics used to test resistance with this bacterial mutation are linezolid and daptomycin. These antibiotics are some of the last resort treatments available and kill the bacteria when they are not in a biofilm. However, the biofilm with the new mutation can tolerate high doses of these antibiotics but cannot survive our immune system.

"The case expands our understanding of the role of the stringent response in susceptibility and tolerance to a wide range of antibiotics, especially in biofilms," Rosch said. "It also demonstrates that these mutations can develop and gain a foothold during a human infection."

The fact that these bacteria have developed pathways to create resistance specifically to antibiotics but ignore developing resistance to an attack by our immune system is an interesting evolutionary turn. These bacteria are evolving to primarily infect immunocompromised patients, where there is no need for them to survive an immune attack.

An experimental antibiotic, ADEP-4, is one of the upcoming treatments in development for bacterial biofilms. ADEP-4 activates an enzyme that kills persister cells and subsequently eliminates the biofilm. Rosch and his team tested resistance in the relA-mutant bacteria with ADEP-4 and reported that the compound is effective in killing the mutant biofilm.

"In the future, compounds like ADEP-4 may provide a new approach to resolving persistent infections," Wolf said.

Sources: AAAS, mBio

About the Author
  • I love all things science and am passionate about bringing science to the public through writing. With an M.S. in Genetics and experience in cancer research, marketing and technical writing, it is a pleasure to share the latest trends and findings in science on LabRoots.
You May Also Like
NOV 23, 2018
Microbiology
NOV 23, 2018
Researchers Surprised to Find Giant Viruses in Forest Soil
Viruses were thought of as tiny infectious agents for the most part, until researchers began to discover more and more giant viruses....
NOV 29, 2018
Genetics & Genomics
NOV 29, 2018
Pet Genomics Might Need to be Leashed
Experts say genetic testing for pets is not quite ready for the market, but that hasn't stopped companies from selling tests....
DEC 05, 2018
Videos
DEC 05, 2018
Promising Results From Early Trials of Gene Therapy for Sickle Cell Anemia
More than 90,000 Americans and millions of people around the world have SCA....
JAN 06, 2019
Genetics & Genomics
JAN 06, 2019
Exploring the Impact of Extensive Newborn Screening
While the exact number now varies by state, newborns are screened for several diseases. Should we be doing more?...
JAN 08, 2019
Microbiology
JAN 08, 2019
Ebola Relative is Discovered
Bats are a vital part of the ecosystem, but they also host deadly viruses. Scientists have now discovered a new filovirus in a bat....
JAN 17, 2019
Genetics & Genomics
JAN 17, 2019
Researchers Link Genetic Variants to Schizophrenia
Small changes in the sequence of the gene that encodes for a neurotransmitter receptor have been linked to the development of schizophrenia....
Loading Comments...